Table 1.

Patient-derived xenograft model characteristics

	PDX model name/tumor ID	TNM	Disease stage	Diagnosis	Treatment prior to tissue collection	Last PDX generation	Expansion of PDX from frozen	Final generation-to-generation expansion time, d	PDX tumor doubling time, d
1	MDA-ATC1	T4bN1bM1	IVC	ATC	No	F5	F4	32	5-7
2	MDA-ATC2	T4aN1aM0	IVB	ATC	No	F4	F4	28	5-6
3	MDA-ATC3	T4aN1M0	IVB	Multifocal clusters of viable carcinoma consistent with residual ATC	Dabrafenib, trametinib	F4	F4	14	4-5
4	MDA-ATC4	T4aN1bM1	IVB	ATC arising associated with PTC	Atezolizumab, vemurafenib, cobimetinib	F5	F3	14	3-5
5	MDA-ATC5	T3aN0M0	IVC	ATC	No	F5	F2	14	3-4
6	MDA-ATC6	T4aN0M0	IVC	ATC focal associated PTC	No	F6	F6	14	3-4

Abbreviations: ATC, anaplastic thyroid cancer; d, days; ID, identification; PDX, patient-derived xenograft; PTC, papillary thyroid cancer.